HMGCS2 silencing attenuates high glucose-induced in vitro diabetic cardiomyopathy by increasing cell viability, and inhibiting apoptosis, inflammation, and oxidative stress. This evidence concerns the gene HMGCS2 and diabetic cardiomyopathy.